Prograf and Ifosfamide drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Prograf (tacrolimus) and Ifosfamide (ifosfamide). Common drug interactions include foetal distress syndrome among females and drug ineffective among males.

The phase IV clinical study analyzes what interactions people have when they take Prograf and Ifosfamide. It is created by eHealthMe based on reports of 9 people who take the same drugs from the FDA, and is updated regularly.

What is Prograf?

Prograf has active ingredients of tacrolimus. It is often used in kidney transplant. eHealthMe is studying from 42,230 Prograf users. Check the latest studies of Prograf.

What is Ifosfamide?

Ifosfamide has active ingredients of ifosfamide. eHealthMe is studying from 21,285 Ifosfamide users. Check the latest studies of Ifosfamide.



On Jul, 21, 2026

9 people who take Prograf and Ifosfamide together, and have interactions are studied.

Prograf and Ifosfamide drug interactions.

What are the common drug interactions of Prograf and Ifosfamide, by gender? *:

female:

  1. Foetal distress syndrome (altered heart rate or rhythm and leading tocompromised blood flow or changes in blood chemistry of foetus)
  2. Maternal exposure during pregnancy (use of substance during pregnancy)
  3. Acute graft versus host disease in skin (acute complication on skin following an allogeneic tissue/blood transplant)
  4. Hodgkin's disease recurrent (cancer originating from white blood cells -recurrent)
  5. Anaphylactic reaction (serious allergic reaction)
  6. Stillbirth (a birth of dead foetus)
  7. Encephalopathy (functioning of the brain is affected by some agent or condition)

male:

  1. Drug ineffective
  2. Graft versus host disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body)
  3. Pseudomonas infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa)
  4. Pyrexia (fever)
  5. Renal failure (kidney dysfunction)
  6. Respiratory distress (difficulty in breathing)
  7. Splenomegaly (enlargement of spleen)
  8. Staphylococcal sepsis (blood infection by an infection with staphylococcus bacteria)
  9. T-cell lymphoma recurrent (reoccurs a blood cell cancer)
  10. Angiocentric lymphoma (extra nodal natural killer cell cancer)

What are the common drug interactions of Prograf and Ifosfamide, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Foetal distress syndrome (altered heart rate or rhythm and leading tocompromised blood flow or changes in blood chemistry of foetus)
  2. Maternal exposure during pregnancy (use of substance during pregnancy)
  3. Acute graft versus host disease in skin (acute complication on skin following an allogeneic tissue/blood transplant)
  4. Hodgkin's disease recurrent (cancer originating from white blood cells -recurrent)
  5. Anaphylactic reaction (serious allergic reaction)
  6. Stillbirth (a birth of dead foetus)

30-39:

  1. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  2. Pseudomonas infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa)
  3. Pyrexia (fever)
  4. Renal failure (kidney dysfunction)
  5. Respiratory distress (difficulty in breathing)
  6. Splenomegaly (enlargement of spleen)
  7. Staphylococcal sepsis (blood infection by an infection with staphylococcus bacteria)
  8. T-cell lymphoma recurrent (reoccurs a blood cell cancer)
  9. Blood lactate dehydrogenase increased
  10. Graft versus host disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body)

40-49:

n/a

50-59:

  1. Encephalopathy (functioning of the brain is affected by some agent or condition)

60+:

  1. Angiocentric lymphoma (extra nodal natural killer cell cancer)
  2. Acute graft versus host disease (acute complication following an allogeneic tissue/blood transplant)
  3. Drug ineffective

* Approximation only. Some reports may have incomplete information.

Do you take Prograf and Ifosfamide?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Prograf and Ifosfamide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Prograf:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Ifosfamide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Prograf and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ifosfamide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on tacrolimus and ifosfamide (the active ingredients of Prograf and Ifosfamide, respectively), and Prograf and Ifosfamide (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: